SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

2022218 citationsReviewhybrid Open Access

Authors

Øystein Karlstad · Norwegian Institute of Public Health

Petteri Hovi · Finnish Institute for Health and Welfare

Anders Husby · Imperial College London

Tommi Härkänen · Finnish Institute for Health and Welfare

Randi Selmer · Norwegian Institute of Public Health

Nicklas Pihlström · Medical Products Agency

Jørgen Vinsløv Hansen

Abstract

Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis. For individuals receiving 2 doses of the same vaccine, risk of myocarditis was highest among young males (aged 16-24 years) after the second dose. These findings are compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after BNT162b2, and between 9 and 28 excess events per 100 000 vaccinees after mRNA-1273. This risk should be balanced against the benefits of protecting against severe COVID-19 disease.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Viral Infections and Immunology Research Animal Virus Infections Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Cardiology

Volume 7, Issue 6, pp. 600-600

DOI: 10.1001/jamacardio.2022.0583

Field-Weighted Citation Impact: 21.23